GJIC
FBRX icon

Gamble Jones Investment Counsel’s Forte Biosciences FBRX Stock Holding History

Gamble Jones Investment Counsel’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-45
Closed -$11K – 215
2019
Q3 		$11K Hold
45
– – ﹤0.01% 203
2019
Q2 		$113K Hold
45
– – 0.01% 208
2019
Q1 		$184K Hold
45
– – 0.02% 203
2018
Q4 		$139K Hold
45
– – 0.01% 202
2018
Q3 		$264K Sell
45
-1
-2% -$3.81K 0.02% 191
2018
Q2 		$162K Hold
46
– – 0.02% 212
2018
Q1 		$206K Hold
46
– – 0.02% 213
2017
Q4 		$178K Buy
+46
New +$184K 0.02% 213

Other funds holding FBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gamble Jones Investment Counsel's FBRX Position: Q4 2019 in Review

Gamble Jones Investment Counsel sold out of Forte Biosciences (FBRX) in Q4 2019, closing a stake of 45 shares — an estimated $11K sold.

Gamble Jones Investment Counsel first reported a position in FBRX in Q4 2017 and held it in 8 quarters. The position peaked at $264K in Q3 2018. 51 funds tracked by Wall St. Rank hold FBRX as of Q4 2019.

  • Gamble Jones Investment Counsel reported no remaining Forte Biosciences position as of Q4 2019 after selling out during the quarter.
  • Gamble Jones Investment Counsel sold 45 Forte Biosciences shares in Q4 2019, an estimated $11K.
  • Gamble Jones Investment Counsel first reported a position in Forte Biosciences in Q4 2017 and held it in 8 quarters.
  • Gamble Jones Investment Counsel's Forte Biosciences position peaked at $264K in Q3 2018.
  • 51 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2019.

Based on Gamble Jones Investment Counsel's 13F filing for Q4 2019, filed 10 Feb 2020.